[en] During the osteoarthritis (OA) process, activation of immune systems, whether innate or adaptive, is strongly associated with low-grade systemic inflammation. This process is initiated and driven in the synovial membrane, especially by synovium cells, themselves previously activated by damage-associated molecular patterns (DAMPs) released during cartilage degradation. These fragments exert their biological activities through pattern recognition receptors (PRRs) that, as a consequence, induce the activation of signaling pathways and beyond the release of inflammatory mediators, the latter contributing to the vicious cycle between cartilage and synovial membrane. The primary endpoint of this review is to provide the reader with an overview of these many molecules categorized as DAMPs and the contribution of the latter to the pathophysiology of OA. We will also discuss the different strategies to control their effects. We are convinced that a better understanding of DAMPs, their receptors, and associated pathological mechanisms represents a decisive issue for degenerative joint diseases such as OA.
Research Center/Unit :
d‐BRU - Dental Biomaterials Research Unit - ULiège [BE]
Disciplines :
Rheumatology
Author, co-author :
Lambert, Cécile ; Université de Liège - ULiège > Département des sciences de la motricité > musculoSkeletal Innovative research Lab (mSKIL)
Zappia, Jérémie ; Université de Liège - ULiège > Département des sciences de la motricité > musculoSkeletal Innovative research Lab (mSKIL)
Sanchez, Christelle ; Université de Liège - ULiège > Département des sciences de la motricité > musculoSkeletal Innovative research Lab (mSKIL)
Kingsbury SR, Gross HJ, Isherwood G, Conaghan PG. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatol. (2014) 53:937–47. 10.1093/rheumatology/ket463
Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. (2012) 64:1697–707. 10.1002/art.34453
Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J Rheumatol. (2015) 42:363–71. 10.3899/jrheum.140382
Lopes EBP, Filiberti A, Husain SA, Humphrey MB. Immune contributions to osteoarthritis. Curr Osteoporos Rep. (2017) 15:593–600. 10.1007/s11914-017-0411-y29098574
Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil. (2015) 23:1233–41. 10.1016/j.joca.2015.03.03625865392
de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, Huizinga TW, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr Cartil. (2012) 20:1484–99. 10.1016/j.joca.2012.08.02722960092
Liu-Bryan R. Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep. (2013) 15:323. 10.1007/s11926-013-0323-523516014
Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. (2012) 51:249–57. 10.1016/j.bone.2012.02.01222387238
Wang H, Wang Q, Yang M, Yang L, Wang W, Ding H, et al. Histomorphology and innate immunity during the progression of osteoarthritis: does synovitis affect cartilage degradation? J Cell Physiol. (2018) 233:1342–58. 10.1002/jcp.2601128513840
Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. (2016) 12:580–92. 10.1038/nrrheum.2016.13627539668
Nefla M, Holzinger D, Berenbaum F, Jacques C. The danger from within: alarmins in arthritis. Nat Rev Rheumatol. (2016) 12:669–83. 10.1038/nrrheum.2016.16227733758
Millerand M, Berenbaum F, Jacques C. Danger signals and inflammaging in osteoarthritis. Clin Exp Rheumatol. (2019) 37:48–56. 31621566
Frevert CW, Felgenhauer J, Wygrecka M, Nastase M V, Schaefer L. Danger-associated molecular patterns derived from the extracellular matrix provide temporal control of innate immunity. J Histochem Cytochem. (2017) 66:213–27. 10.1369/002215541774088029290139
Chung HY, Kim DH, Lee EK, Chung KW, Chung S, Lee B, et al. Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept. Aging Dis. (2019) 10:367–82. 10.14336/AD.2018.032431011483
O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. (2013) 13:453–60. 10.1038/nri344623681101
Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis: a critical review of the state-of-the-art, current prospects, and future challenges. Bone. (2016) 85:81–90. 10.1016/j.bone.2016.01.01926812612
Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol. (2009) 90:463–79. 10.1111/j.1365-2613.2009.00676.x19765101
Homandberg GA, Hui F. Association of proteoglycan degradation with catabolic cytokine and stromelysin release from cartilage cultured with fibronectin fragments. Arch Biochem Biophys. (1996) 334:325–31. 10.1006/abbi.1996.04618900407
Hwang HS, Park SJ, Cheon EJ, Lee MH, Kim HA. Fibronectin fragment-induced expression of matrix metalloproteinases is mediated by MyD88-dependent TLR-2 signaling pathway in human chondrocytes. Arthritis Res Ther. (2015) 17:320. 10.1186/s13075-015-0833-926563875
Su SL, Tsai CD, Lee CH, Salter DM, Lee HS. Expression and regulation of Toll-like receptor 2 by IL-1beta and fibronectin fragments in human articular chondrocytes. Osteoarthr Cartil. (2005) 13:879–86. 10.1016/j.joca.2005.04.01715961329
Avenoso A, D'Ascola A, Scuruchi M, Mandraffino G, Calatroni A, Saitta A, et al. Hyaluronan in experimental injured/inflamed cartilage: in vivo studies. Life Sci. (2018) 193:132–40. 10.1016/j.lfs.2017.11.00629126884
Marcellin E, Steen JA, Nielsen LK. Insight into hyaluronic acid molecular weight control. Appl Microbiol Biotechnol. (2014) 98:6947–56. 10.1007/s00253-014-5853-x24957250
Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. (2002) 195:99–111. 10.1084/jem.2000185811781369
Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem. (2009) 284:12762–71. 10.1074/jbc.M80608420019258328
Sofat N, Robertson SD, Hermansson M, Jones J, Mitchell P, Wait R. Tenascin-C fragments are endogenous inducers of cartilage matrix degradation. Rheumatol Int. (2012) 32:2809–17. 10.1007/s00296-011-2067-821874326
Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. (2009) 15:774–80. 10.1038/nm.198719561617
Zuliani-Alvarez L, Marzeda AM, Deligne C, Schwenzer A, McCann FE, Marsden BD, et al. Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers. Nat Commun. (2017) 8:1595. 10.1038/s41467-017-01718-729150600
Chavez RD, Sohn P, Serra R. Prg4 prevents osteoarthritis induced by dominant-negative interference of TGF-ß signaling in mice. PLoS ONE. (2019) 14:587 10.1371/journal.pone.021060130629676
Iqbal SM, Leonard C, S CR, De Rantere D, Tailor P, Ren G, et al. Lubricin/Proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep. (2016) 6:18910. 10.1038/srep1891026752378
Zappia J, Joiret M, Sanchez C, Lambert C, Geris L, Muller M, et al. From translation to protein degradation as mechanisms for regulating biological functions: a review on the SLRP family in skeletal tissues. Biomolecules. (2020) 10:80. 10.3390/biom1001008031947880
Sjoberg A, Onnerfjord P, Morgelin M, Heinegard D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. (2005) 280:32301–8. 10.1074/jbc.M50482820016046396
Sjoberg AP, Manderson GA, Morgelin M, Day AJ, Heinegard D, Blom AM. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol. (2009) 46:830–9. 10.1016/j.molimm.2008.09.01818962898
Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. (2005) 115:2223–33. 10.1172/JCI2375516025156
Barreto G, Soininen A, Ylinen P, Sandelin J, Konttinen YT, Nordstrom DC, et al. Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis. Arthritis Res Ther. (2015) 17:379. 10.1186/s13075-015-0902-026703441
Avenoso A, D'Ascola A, Scuruchi M, Mandraffino G, Calatroni A, Saitta A, et al. The proteoglycan biglycan mediates inflammatory response by activating TLR-4 in human chondrocytes: inhibition by specific siRNA and high polymerized Hyaluronan. Arch Biochem Biophys. (2018) 640:75–82. 10.1016/j.abb.2018.01.00729339093
Silawal S, Triebel J, Bertsch T, Schulze-Tanzil G. Osteoarthritis and the complement cascade. Clin Med Insights Arthritis Musculoskelet Disord. (2018) 11:1179544117751430. 10.1177/117954411775143029434479
Blasioli DJ, Kaplan DL. The roles of catabolic factors in the development of osteoarthritis. Tissue Eng Part B Rev. (2014) 20:355–s63. 10.1089/ten.teb.2013.037724172137
Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol. (2007) 82:657–65. 10.1189/jlb.120673017575266
McFadden JP, Basketter DA, Dearman RJ, Kimber IR. Extra domain A-positive fibronectin-positive feedback loops and their association with cutaneous inflammatory disease. Clin Dermatol. (2011) 29:257–65. 10.1016/j.clindermatol.2010.11.00321496732
Kelsh R, You R, Horzempa C, Zheng M, McKeown-Longo PJ. Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains. PLoS ONE. (2014) 9:e102974. 10.1371/journal.pone.010297425051083
Klatt AR, Paul-Klausch B, Klinger G, Kuhn G, Renno JH, Banerjee M, et al. A critical role for collagen II in cartilage matrix degradation: collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res. (2009) 27:65–70. 10.1002/jor.2071618655132
Ruettger A, Schueler S, Mollenhauer JA, Wiederanders B. Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J Biol Chem. (2008) 283:1043–51. 10.1074/jbc.M70491520017991740
Fichter M, Korner U, Schomburg J, Jennings L, Cole AA, Mollenhauer J. Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytes. J Orthop Res. (2006) 24:63–70. 10.1002/jor.2000116419970
Tchetina EV, Kobayashi M, Yasuda T, Meijers T, Pidoux I, Poole AR. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biol. (2007) 26:247–58. 10.1016/j.matbio.2007.01.00617306969
Yasuda T. Type II collagen peptide stimulates Akt leading to nuclear factor-kappaB activation: its inhibition by hyaluronan. Biomed Res. (2014) 35:193–9. 10.2220/biomedres.35.19324942858
Lambert C, Borderie D, Dubuc JE, Rannou F, Henrotin Y. Type II collagen peptide Coll2-1 is an actor of synovitis. Osteoarthr Cartil. (2019) 27:1680–91. 10.1016/j.joca.2019.07.00931325494
Lees S, Golub SB, Last K, Zeng W, Jackson DC, Sutton P, et al. Bioactivity in an Aggrecan 32-mer fragment is mediated via toll-like receptor 2. Arthritis Rheumatol. (2015) 67:1240–9. 10.1002/art.3906325707860
Kalchishkova N, Furst CM, Heinegard D, Blom AM. NC4 Domain of cartilage-specific collagen IX inhibits complement directly due to attenuation of membrane attack formation and indirectly through binding and enhancing activity of complement inhibitors C4B-binding protein and factor H. J Biol Chem. (2011) 286:27915–26. 10.1074/jbc.M111.24283421659506
Happonen KE, Saxne T, Aspberg A, Morgelin M, Heinegard D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. (2010) 62:3574–83. 10.1002/art.2772020737467
Groeneveld TWL, Oroszlán M, Owens RT, Faber-Krol MC, Bakker AC, Arlaud GJ, et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol. (2005) 175:4715–23. 10.4049/jimmunol.175.7.471516177119
Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. (2008) 8:212–6. 10.1038/nrc234518292776
Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthr Cartil. (2010) 18:82–7. 10.1016/j.joca.2009.07.00919747583
Ding F, Wang J, Zhu G, Zhao H, Wu G, Chen L. Osteopontin stimulates matrix metalloproteinase expression through the nuclear factor-kappaB signaling pathway in rat temporomandibular joint and condylar chondrocytes. Am J Transl Res. (2017) 9:316–29. 28337262
Tardelli M, Zeyda K, Moreno-Viedma V, Wanko B, Grun NG, Staffler G, et al. Osteopontin is a key player for local adipose tissue macrophage proliferation in obesity. Mol Metab. (2016) 5:1131–7. 10.1016/j.molmet.2016.09.00327818939
Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther. (2012) 14:R7. 10.1186/ar355522225630
Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther. (2007) 9:R36. 10.1186/ar217217407561
Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. (2005) 52:3492–501. 10.1002/art.2137316255041
Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. (2001) 167:2887–94. 10.4049/jimmunol.167.5.288711509636
van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, et al. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum. (2012) 64:1466–76. 10.1002/art.3431522143922
Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW, Mort JS, et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. (2012) 64:1477–87. 10.1002/art.3349522127564
Ruan G, Xu J, Wang K, Zheng S, Wu J, Bian F, et al. Associations between serum IL-8 and knee symptoms, joint structures, and cartilage or bone biomarkers in patients with knee osteoarthritis. Clin Rheumatol. (2019) 38:3609–17. 10.1007/s10067-019-04718-8
van den Bosch MH, Blom AB, Schelbergen RF, Vogl T, Roth JP, Sloetjes AW, et al. Induction of canonical Wnt signaling by the alarmins S100A8/A9 in murine knee joints: implications for osteoarthritis. Arthritis Rheumatol. (2016) 68:152–63. 10.1002/art.3942026360647
Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood. (2010) 115:549–58. 10.1182/blood-2009-06-22694419965653
Song C, Zhou X, Dong Q, Fan R, Wu G, Ji B, et al. Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10. Inflamm Res. (2012) 61:1219–27. 10.1007/s00011-012-0519-622797859
Nakashima M, Sakai T, Hiraiwa H, Hamada T, Omachi T, Ono Y, et al. Role of S100A12 in the pathogenesis of osteoarthritis. Biochem Biophys Res Commun. (2012) 422:508–14. 10.1016/j.bbrc.2012.05.03622609404
Wang LC, Zhang HY, Shao L, Chen L, Liu ZH, He X, et al. S100A12 levels in synovial fluid may reflect clinical severity in patients with primary knee osteoarthritis. Biomarkers. (2013) 18:216–20. 10.3109/1354750X.2013.76626223557130
Meijer B, Gearry RB, Day AS. The role of S100A12 as a systemic marker of inflammation. Int J Inflam. (2012) 2012:907078. 10.1155/2012/90707822811950
Baillet A, Trocme C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology. (2010) 49:671–82. 10.1093/rheumatology/kep45220100792
Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med. (2014) 20:138–46. 10.2119/molmed.2013.0016424531836
Ke X, Jin G, Yang Y, Cao X, Fang R, Feng X, et al. Synovial fluid HMGB-1 levels are associated with osteoarthritis severity. Clin Lab. (2015) 61:809–18. 10.7754/Clin.Lab.2015.14120526299081
Terada C, Yoshida A, Nasu Y, Mori S, Tomono Y, Tanaka M, et al. Gene expression and localization of high-mobility group box chromosomal protein-1 (HMGB-1)in human osteoarthritic cartilage. Acta Med Okayama. (2011) 65:369–77. 10.18926/AMO/4726222189477
Garcia-Arnandis I, Guillen MI, Gomar F, Pelletier JP, Martel-Pelletier J, Alcaraz MJ. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. Arthritis Res Ther. (2010) 12:R165. 10.1186/ar312420799933
Busso N, So A. Microcrystals as DAMPs and their role in joint inflammation. Rheumatology. (2012). 51:1154–60. 10.1093/rheumatology/ker52422332122
McAllister MJ, Chemaly M, Eakin AJ, Gibson DS, McGilligan VE. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthr Cartil 756. (2018) 26:612–19. 10.1016/j.joca.2018.02.90129499288
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. (2006) 440:237–41. 10.1038/nature0451616407889
Denoble AE, Huffman KM, Stabler T V, Kelly SJ, Hershfield MS, McDaniel GE, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA. (2011) 108:2088–93. 10.1073/pnas.101274310821245324
Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol. (2005) 174:5016–23. 10.4049/jimmunol.174.8.501615814732
Barreto G, Manninen M, Eklund KK. Osteoarthritis and toll-like receptors: when innate immunity meets chondrocyte apoptosis. Biology. (2020) 9:772 10.3390/biology904006532235418
Parker LC, Prince LR, Sabroe I. Translational mini-review series on toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol. (2007) 147:199–207. 10.1111/j.1365-2249.2006.03203.x17223959
Gomez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G. TLR4 signalling in osteoarthritis–finding targets for candidate DMOADs. Nat Rev Rheumatol. (2015) 11:159–70. 10.1038/nrrheum.2014.20925512010
Kim HA, Cho M-L, Choi HY, Yoon CS, Jhun JY, Oh HJ, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum. (2006) 54:2152–63. 10.1002/art.2195116802353
Rosenberg JH, Rai V, Dilisio MF, Agrawal DK. Damage-associated molecular patterns in the pathogenesis of osteoarthritis: potentially novel therapeutic targets. Mol Cell Biochem. (2017) 434:171–9. 10.1007/s11010-017-3047-428474284
Barreto G, Sandelin J, Salem A, Nordstrom DC, Waris E. Toll-like receptors and their soluble forms differ in the knee and thumb basal osteoarthritic joints. Acta Orthop. (2017) 88:326–33. 10.1080/17453674.2017.128105828093922
McCormack WJ, Parker AE, O'Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther. (2009) 11:243. 10.1186/ar272919835640
Mullen LM, Chamberlain G, Sacre S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther. (2015) 17:122. 10.1186/s13075-015-0645-y25975607
Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity. (2012) 36:388–400. 10.1016/j.immuni.2012.01.01822444631
Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. (2013) 25:2185–97. 10.1016/j.cellsig.2013.06.01323838007
Sun XH, Liu Y, Han Y, Wang J. Expression and significance of high-mobility group protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in knee osteoarthritis. Med Sci Monit. (2016) 22:2105–12. 10.12659/MSM.89568927320800
Campo GM, Avenoso A, D'Ascola A, Prestipino V, Scuruchi M, Nastasi G, et al. Hyaluronan differently modulates TLR-4 and the inflammatory response in mouse chondrocytes. BioFactors. (2012) 38:69–76. 10.1002/biof.20222287316
Campo GM, Avenoso A, D'Ascola A, Scuruchi M, Prestipino V, Nastasi G, et al. Adenosine A2A receptor activation and hyaluronan fragment inhibition reduce inflammation in mouse articular chondrocytes stimulated with interleukin-1beta. FEBS J. (2012) 279:2120–33. 10.1111/j.1742-4658.2012.08598.x22502642
de Seny D, Cobraiville G, Charlier E, Neuville S, Esser N, Malaise D, et al. Acute-phase serum amyloid A in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS ONE. (2013) 8:815 10.1371/journal.pone.006676923776697
Roman-Blas JA, Bizzi E, Largo R, Migliore A, Herrero-Beaumont G. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin Pharmacother. (2016) 17:1745–56. 10.1080/14656566.2016.120107027326466
Wang P, Zhu F, Konstantopoulos K. Interleukin-6 synthesis in human chondrocytes is regulated via the antagonistic actions of prostaglandin (PG)E2 and 15-deoxy-delta(12,14)-PGJ2. PLoS ONE. (2011) 6:e27630. 10.1371/journal.pone.002763022096605
Juarranz Y, Gutierrez-Canas I, Arranz A, Martinez C, Abad C, Leceta J, et al. VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts. Ann N Y Acad Sci. (2006) 1070:359–64. 10.1196/annals.1317.04516888192
Villalvilla A, da Silva JA, Largo R, Gualillo O, Vieira PC, Herrero-Beaumont G, et al. 6-Shogaol inhibits chondrocytes' innate immune responses and cathepsin-K activity. Mol Nutr Food Res. (2014) 58:256–66. 10.1002/mnfr.20120083324039109
Komai-Koma M, Li D, Wang E, Vaughan D, Xu D. Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice. Immunology. (2014) 143:354–62. 10.1111/imm.1231224801735
Alquraini A, Garguilo S, D'Souza G, Zhang LX, Schmidt TA, Jay GD, et al. The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther. (2015) 17:353. 10.1186/s13075-015-0877-x26643105
Peng Y, Park H-S, Tang LA, Horwitz N, Lin L. Generation of sRAGEhigh transgenic mice to study inflammaging. Front Biosci. (2019) 24:555–63. 10.2741/473530468673
Patriquin CJ, Kuo KHM. Eculizumab and beyond: the past, present, and future of complement therapeutics. Transfus Med Rev. (2019) 33:256–65. 10.1016/j.tmrv.2019.09.00431703946
Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. (2011) 17:1039–44. 10.2119/molmed.2010.0026421666956
Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, de Torre-Minguela C, Cerón-Carrasco JP, Pérez-Sánchez H, Arostegui JI, et al. MCCcloses the active conformation of NLRP3 to an inactive state. Nat Chem Biol. (2019) 15:560–4. 10.1038/s41589-019-0278-631086329
Hsieh LT, Nastase M V, Zeng-Brouwers J, Iozzo R V, Schaefer L. Soluble biglycan as a biomarker of inflammatory renal diseases. Int J Biochem Cell Biol. (2014) 54:223–35. 10.1016/j.biocel.2014.07.02025091702
Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med. (2011) 270:309–18. 10.1111/j.1365-2796.2011.02432.x21793951
